A Phase III Clinical Trial Evaluating DCVax-L Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM)

Trial Profile

A Phase III Clinical Trial Evaluating DCVax-L Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
  • Indications Brain cancer; Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Northwest Biotherapeutics
  • Most Recent Events

    • 31 May 2018 According to a Northwest Biotherapeutics media release, interim data will be discussed the ASCO Conference 2018.
    • 29 May 2018 Results presented in the Northwest Biotherapeutics Media Release.
    • 29 May 2018 According to a Northwest Biotherapeutics media release, interim survival data were published in the Journal of Translational Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top